| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8827015 | Transplantation Proceedings | 2018 | 4 Pages |
Abstract
In low-immunologic risk KT recipients who received tacrolimus, mycophenolic acid, and steroid therapy, thymoglobulin induction therapy significantly reduced the incidence of biopsy-proven acute rejection and borderline change compared with basiliximab induction therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
H. Lee, S. Lee, J.S. Jeon, S.H. Kwon, H. Noh, D.C. Han, S. Yun, D. Song,